LIRAGLUTIDE | A214568 | TEVA PHARMACEUTICALS DEVELOPMENT INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Novo Nordisk Inc. et al v. Teva Pharmaceuticals, Inc. et al 17 patentsANDA 214568liraglutide recombinant | D. Del. | 2021-12-21 | Terminated 2023-09-25 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$63.18
per ml
Lowest NADAC/Unit
$63.18
per ml
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00480725046LIRAGLUTIDE 5-PAK 18 MG/3 ML | $63.18 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
| Code | Date | Status |
|---|---|---|
| PC | Feb 24, 2026 | Expired |